Outcomes in patients with suspected PE (data from various sources)
| Test accuracy results . | Consequences . | Results from published SR36 . | Results from treatment guideline, %37 . | Targeted search of outcomes studies38 . | Panel survey results (1 y), % . |
|---|---|---|---|---|---|
| TP | Mortality: all cause | NR | 2.0 (6 mo) | 9.8% (3 mo) Recurrent PE population: 46.8% (3 mo) | 11.3 |
| Mortality: from PE at 3-6 mo | 1.5% (3 mo) | 0.1 (6 mo) | 2.8% (3 mo) Recurrent PE population: 51.9% (3 mo) | ||
| Recurrence of PE on anticoagulation | NR | 1.0 (6 mo) | 3.7% (3 mo) | 3.0 | |
| CTEPH | NR | NR | NR | 4.2 | |
| Major bleeding | NR | 2.1 (6 mo) | 5.2% (1 mo), 6.7% (3 mo) | 3.3 | |
| Fatal major bleeding | NR | 0.2 (6 mo) | NR | ||
| Hemorrhagic stroke | NR | NR | 0.6% (3 mo) | 1.7 | |
| FP | Mortality: all cause | NR | NR | ||
| Major bleeding | NR | 2.1 (6 mo) | 6.7% (3 mo) | 3.3 | |
| Fatal major bleeding | NR | 0.2 (6 mo) | NR | NR | |
| TN | Mortality: from PE at 3 mo | NR | NR | 0.2% (3 mo) | NR |
| FN | Mortality: all cause | NR | NR | 40.0% (3 mo) | 30.5 |
| Mortality: from PE at 3-12 mo | NR | NR | 5.0% (3 mo) | 27.8 | |
| Recurrence of PE at 3-12 mo | NR | NR | NR | 23 |
| Test accuracy results . | Consequences . | Results from published SR36 . | Results from treatment guideline, %37 . | Targeted search of outcomes studies38 . | Panel survey results (1 y), % . |
|---|---|---|---|---|---|
| TP | Mortality: all cause | NR | 2.0 (6 mo) | 9.8% (3 mo) Recurrent PE population: 46.8% (3 mo) | 11.3 |
| Mortality: from PE at 3-6 mo | 1.5% (3 mo) | 0.1 (6 mo) | 2.8% (3 mo) Recurrent PE population: 51.9% (3 mo) | ||
| Recurrence of PE on anticoagulation | NR | 1.0 (6 mo) | 3.7% (3 mo) | 3.0 | |
| CTEPH | NR | NR | NR | 4.2 | |
| Major bleeding | NR | 2.1 (6 mo) | 5.2% (1 mo), 6.7% (3 mo) | 3.3 | |
| Fatal major bleeding | NR | 0.2 (6 mo) | NR | ||
| Hemorrhagic stroke | NR | NR | 0.6% (3 mo) | 1.7 | |
| FP | Mortality: all cause | NR | NR | ||
| Major bleeding | NR | 2.1 (6 mo) | 6.7% (3 mo) | 3.3 | |
| Fatal major bleeding | NR | 0.2 (6 mo) | NR | NR | |
| TN | Mortality: from PE at 3 mo | NR | NR | 0.2% (3 mo) | NR |
| FN | Mortality: all cause | NR | NR | 40.0% (3 mo) | 30.5 |
| Mortality: from PE at 3-12 mo | NR | NR | 5.0% (3 mo) | 27.8 | |
| Recurrence of PE at 3-12 mo | NR | NR | NR | 23 |
SR, systematic review.